MSKCC, New York, NY
Adam Jacob Schoenfeld , Joseph Minhow Chan , Hira Rizvi , Natasha Rekhtman , Yahya Daneshbod , Daisuke Kubota , Jason C. Chang , Maria E. Arcila , Marc Ladanyi , Romel Somwar , Mark G. Kris , Dana Pe'er , Gregory J. Riely , Helena Alexandra Yu
Background: Even though osimertinib (osi) is now the initial treatment for patients with EGFR-mutant lung cancers, our knowledge about mechanisms of resistance (MOR) is largely derived from patients who received osi after developing acquired resistance to initial EGFR inhibitor. Further, studies of osi resistance to date have mainly reported genotyping of plasma which suboptimally detects lineage plasticity, copy number changes, and chromosomal rearrangements. Methods: To identify MOR to osi and characterize clinical, molecular and histologic factors associated with duration of response, we identified patients with EGFR-mutant lung cancers who had next-generation sequencing performed on tumor tissue after developing acquired resistance to osi. Results: From January 2016 to December 2018, post-osi tumor tissue was collected from 71 patients (42 with paired pre-treatment specimens). See mechanisms of resistance below. Histologic transformation was identified in 19% of initial cases and 14% of all cases. When osi is given as initial treatment, with median follow up of 17 months, early emerging MOR rarely included on-target resistance mechanisms (1/16 cases of acquired EGFR G724S). Acquired alterations representing potential resistance mechanisms included CCNE1 and MYC amplifications, and mutations in MTOR and MET H1094Y. We confirmed in preclinical studies that an amino acid substitution at MET H1094 can reduce sensitivity to osi. Conclusions: In this analysis of MOR identified on NGS from tumor tissue, we found a different spectrum of resistance mechanisms to initial and later-line osi, with histologic transformation (including squamous cell transformation) a dominant MOR, particularly in the first-line setting, that cannot be identified on plasma testing. Subsequent studies are needed to assess patients with a longer time on initial osi as there may be a temporal bias to MOR, with off-target MOR emerging earlier and on-target resistance mutations later.
First line (n = 16) | Later line (n = 55) | All (n = 71) | |
---|---|---|---|
Squamous transformation | 2 | 3 | 5 |
Small cell transformation | 1 | 4 | 5 |
On target mutation (EGFR C797X or other) | 1 | 10 | 11 |
Loss of T790M | - | 17 | 17 |
Fusions (ALK, RET, BRAF) | 0 | 5 | 5 |
Amplifications (HER2, MET, EGFR) | 2 | 7 | 9 |
Off target mutations (KRAS, BRAF, HER2) | 1 | 4 | 5 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Tian Li
2023 ASCO Annual Meeting
First Author: Zofia Piotrowska
2022 ASCO Annual Meeting
First Author: Noura J. Choudhury
2020 ASCO Virtual Scientific Program
First Author: Yukti Choudhury